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carcinomas, whereas bcl12 and apoptosis are not
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Summary We report a pilot study on the Fas receptor (APO-1, CD95) in vivo in 15 human squamous cell (non-small) carcinomas and ten
normal bronchial specimens. The principal aim was to investigate whether the so-called death receptor, Fas, is present in these tumours.
Ligation of Fas promptly induces apoptosis, particularly in T Jurkat cells in vitro, and expression of Fas on human cancer would thus
theoretically be of great interest. The immunoreactivity for the anti-apoptotic protein Bcl-2 was also investigated, and the degree of apoptosis
was evaluated by TdT dUTP nick end labelling (TUNEL) and conventional morphological criteria. Fas was present in all initial tumours but
absent in control tissue, that is in the potential precursor cells of bronchial epithelium (P = 0.001). Fas was not detectable after radiotherapy
(P = 0.03). We propose that radiotherapy induces an early selection of tumour cells rather than a down-regulation of Fas. Both Bcl-2 and
apoptosis (TUNEL) were generally expressed at a modest level. In agreement with other studies, we did not find any significant correlation
between Bcl-2 and prognosis, or between Bcl-2 and TUNEL. Hence, in this preliminary report, we have demonstrated Fas receptor in human
squamous cell carcinomas in vivo. This is a novel finding, and the apparent absence of Fas after radiotherapy may have importanttherapeutic
implications.
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Squamous cell carcinoma accounts for approximately 35% of all
human lung carcinomas and originates often in a central or hilar
location (Faber, 1991). The principal non-surgical therapeutic aim
is either to reduce tumour cell proliferation rate and/or to increase
tumour cell death, i.e. to reduce the net tumour growth. The two
main mechanisms ofcell death are necrosis and apoptosis (Wyllie,
1985). Apoptosis has a major influence on net tumour growth
(Arends et al, 1994) and is characterized by successive fragmenta-
tion of DNA, which in most cell types eventually results in 180-
bp-sized fragments. Ligation with the Fas ligand to the Fas
receptor (APO-1, CD95) induces apoptosis, particularly in
cultured human T Jurkat cells but also in human B cells, cultured
human rhabdomyosarcoma cells (Yonehara et al, 1989) and
murine fibroblast L929 cells and T-cell lymphoma WR19L cells
(Itoh and Nagata, 1993; Firestein et al, 1995). So far, the Fas
receptor has not been investigated in depth in human cells in vivo.
In the literature, we have found only a few papers reporting Fas in
vivo, e.g. on certain fibroblasts and fibroblast-like synoviocytes
and on neuroblastoma tumour cells (Aggarwal et al, 1995;
Firestein et al, 1995; Koizumi et al, 1995). Its possible presence on
human cell types other than T cells may open new approaches
concerning both research and eventually therapy.
In this study, we have also included immunocytochemical
investigation of the Bcl-2 protein. The bcl-2 survival proto-
oncogene encodes for a 26-kDa protein that protects cells from
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apoptosis, favouring a prolonged survival of normal as well as
neoplastic cells (Vaux et al, 1988; Nunez et al, 1990; Pezzella et al,
1993; Doglioni et al, 1994; Pilotti et al, 1994). This protein, in a
way similar to metalloproteins, can hinder the apoptotic transduc-
tion signals. As a measure ofapoptosis, we applied TUNEL (TdT
dUTP nick end labelling) to the carcinomas and related the find-
ings with morphological signs ofapoptotic death.
We report that all carcinomas expressed the Fas receptor, while
most specimens from non-neoplastic control bronchial tissue
lacked Fas, and Fas apparently disappears during radiotherapy.
The Bcl-2 protein varied between tumours but was relatively
sparsely expressed. Apoptosis, evaluated by TUNEL, was only
moderately pronounced in some tumours, before treatment as well
as after treatment.
MATERIALS AND METHODS
Tissue samples
Biopsy specimens were obtained by bronchoscopy from eight
patients with bronchial squamous cell carcinoma. We felt it imper-
ative toobtain initial biopsies before any kind oftreatment and also
to be able to perform a biopsy after the therapy given. Hence, this
study included a rather small number of patients, however statis-
tical analysis was still possible. In three of the patients with carci-
noma, macroscopical normal bronchial mucosal biopsies from the
contralateral non-neoplastic lung were obtained. Specimens were
thus taken both before and after therapy (fractionated radiotherapy
in cases 2, 3, 4, 6 and 7 and low-dose-rate brachytherapy in cases 1
and 5). One patient has not yet received radiotherapy. Bronchial
muscosal biopsy specimens were also obtained from seven
subjects with non-neoplastic, non-inflammatory lung disease.
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Figure 1 (A) Positive immunoreactivity for Fas in a moderately well-
differentiated lung squamous cell carcinoma (case 5, Fas, Clone UB-2, Oncor,
USA x 450). (B) A squamous carcinoma with a moderate Bcl-2 staining
intensity, although the extent of the immunoreactivity is high (case 2, Bcl-2,
DAKO, Denmark, x 450). (C) Photomicrograph of a squamous cell carcinoma
in which several cells show nuclear TUNEL positivity. Note the apoptotic
morphology ofTUNEL-positive cells (case 6, TUNEL, Oncor, USA, x 380)
Because of the small size of most biopsy specimens, we were only
able to cut a few sections in most cases. During processing
(microwave heating, etc.) some sections were lost, and the ability
to repeat certain investigations was not always possible.
Immunocytochemistry and TUNEL
For each case, 4 to 5-pm-thick sections were cut from representa-
tive blocks. One section was routinely stained with haematoxylin
and eosin, and other sections were placed on pretreated slides
(poly-L-lysine) for later heating in a microwave oven before
immunostaining and TUNEL. All slides were coded and the
examiners had no access to clinical data.
Sections for immunocytochemistry were treated with 3%
hydrogen peroxide in distilled water to inhibit endogenous peroxi-
dase activity and then immersed in boiling citrate buffer, pH 6, in a
microwave oven (Shi et al, 1991) with two changes of 7 min each.
After washing in tap water and distilled water, the sections were
subsequently incubated with (1) 1:20 dilution of normal rabbit
serum for 20 min at room temperature, (2) 1:25 dilution of the
monoclonal anti-Fas antibody (anti-human Fas, Clone UB-2,
murine, Oncor, Gaithersburg, MD, USA) and 1:50 dilution of the
monoclonal antibody to Bcl-2 protein, overnight at +4°C, (3)
1:200 dilution of a biotinylated rabbit antiserum to mouse
immunoglobulins for 30 min at room temperature and (4) 1:100
dilution ofthe streptavidin-biotinylated peroxidase complex for 30
min, also at room temperature. Peroxidase activity was developed
in diaminobenzidine (DAB) chromogene substrate. All reagents
were bought from Dako (Copenhagen, Denmark).
A known positive control for Bcl-2 [a formalin-fixed, paraffin-
embedded follicular lymphoma carrying the (t 14;18) chromo-
somal translocation] was immunostained with the test samples.
Neoplastic cells showing definite cytoplasmic staining of the same
intensity, or higher, as shown by the lymphoma cells, were graded
as 3+. Tumour cells with moderate intensity staining reaction were
graded 2+, weakly positive cells 1+ and tumour cells lacking
immunoreactivity were recorded as negative. In most tumours,
there were scattered lymphocytes, which served as further internal
positive controls. Negative control sections (in which the specific
monoclonal antibody was substituted with the immunoglobulin
fraction of non-immune mouse sera) remained unstained. The
extent of immunoreactivity was evaluated as 1+ if less then 25%
of tumour cells were positive, 2+ if 25-75% were positive and 3+
if more than 75% of cells were positive. Only tumours with cells
showing an intensity of 2+ and 3+ were recorded as positive.
T Jurkat cells were used as positive controls for Fas immuno-
staining (Jurkat E6.1, ECACC number 88042803, CAMR,
Salisbury, Wiltshire, UK). T Jurkat cells were cultured, spun to a
pellet, fixed in 4% formalin and embedded in paraffin. Sections
were cut, treated identically to the test samples and used in each
run as positive controls for Fas. Another monoclonal antibody was
also tested and used in every sample (clone CH-11, Oncor,
Gaithersburg, MD, USA); furthermore, both antibodies were
tested repeatedly on frozen lung squamous carcinoma, all with a
satisfactory result. Fas was registered as positive in test samples if
the immunoreactivity had the same, or almost equal, intensity to
that seen in the Jurkat pellet sections.
Sections for the TUNEL reaction were after deparaffinization
digested by 20gg ml proteinase K for 15 min. After four washes
in distilled water and quenching in 2.0%o hydrogen paroxide, the
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Table 1 Immunoreactivity of Fas and Bcl-2, and end labelling (TUNEL) in
human lung carcinomas and healthy bronchial mucosae
Case Fas Bcl-2 TUNEL Comment
(biopsy before and aftertherapy)
1 Pos ++ +++ Initial biopsy
Neg + Neg After radiotherapy
2 Pos ++ +++ Initial biopsy
Neg ++ +++ After radiotherapy
3 Pos +++ + Initial biopsy
Pos +++ ++ After radiotherapy
4 Pos Neg Lost Initial biopsy
Neg Neg ++ After radiotherapy
5 Pos ++ Neg Initial biopsy
Neg Neg +++ After radiotherapy
6 Pos Neg +++ Initial biopsy
Pos Neg Neg After radiotherapy
7 Pos ++ Neg Initial biopsy
Neg Neg +++ After radiotherapy
8 Pos + +++ Initial biopsy
Controls
A Neg Lost Neg
B Pos + Neg
C Neg Neg Neg
D Neg Neg Neg
E Neg Neg Neg
F Neg +++ Neg
G Pos ++ Neg
H Neg Neg +++ Contralateral bronchus to case 5
Neg Neg Lost Contralateral bronchus to case 6
J Neg Neg Neg Contralateral bronchus to case 7
Pos, positive; neg, negative; lost, sections lost during staining procedures.
Bcl-2: +, < 25% of cells positive; ++, 25-75% positive; and +++, > 75%
positive. TUNEL: +, < 5% of cells positive; ++, 5-25% positive; and +++,
> 25% positive cells.
Apoptag kit was applied according to the manufacturer's instruc-
tions (Oncor, Gaithersburg, MD, USA). Briefly, the TUNEL
method is a tailing reaction in which residues of digoxigenin
nucleotide are analytically added to DNA by terminal deoxy-
nucleotidyl transferase (TdT). The incorporated nucleotides form
a random heteropolymer of digoxigenin-1 -dUTP and dATP in a
ratio that has been optimized for anti-digoxigenin antibody
binding. The positivity was evaluated as 1+ when < 5% oftumour
cells showed a distinct nuclear staining (with an intensity equal or
almost equal to that ofthe control), 2+ if > 5% but less than 25%
were positive and 3+ when more than 25% of tumour cells were
positive. Only TUNEL-positive cells with chromosome condensa-
tion and nuclear fragmentation were regarded as positive, thus
confirming the good and appropriate use of this technique.
Tumours with no positive cells, or the occasional positive cell
only, were recorded as negative. Samples in which TdT was
substituted with water served as negative controls and, as positive
control, DNAase I was added to the samples (20 min at 37°C). The
DNAase was added after quenching in hydrogen peroxide, thus
producing DNA breaks in virtually all cells (Gavrieli et al, 1992).
Statistics
Fischer's exact test was used for analysis ofdifferences in expres-
sion ofFas (and TUNEL) in initial cancer specimens and controls,
and the McNemar test was used for analysis of differences
between initial cancer specimens and specimens from treated
tumours. The Wilcoxon test was used for analysis of differences
between initial specimens and specimens from treated tumours
concerning TUNEL. The Spearman rank correlation test was used
for investigation of any correlation between Bcl-2 and TUNEL.
RESULTS
Fas
The Fas receptor was present in all eight initial squamous cell
carcinoma biopsies, with an intensity equal or almost equal to that
of the T Jurkat pellet control sections (Figure IA). Fas was only
found in two of the ten non-neoplastic bronchial mucosal biopsies
(Table 1) (P < 0.001). Fas was absent in five ofthe seven biopsies
taken from residual (or recurrent) tumour after treatment. (In one
case, no biopsy has been taken aftertreatment, i.e. case 8.) Fas was
not detectable in tumours afterradiotherapy (P = 0.03). None ofthe
tumours show morphological evidence ofnecrosis. The ten control
biopsies showed a mixture of respiratory epithelium and meta-
plastic squamous epithelium, and all lacked morphological atypia.
Bc1-2
There was no significant difference in the expression of Bcl-2
between the initial carcinoma specimens and the controls (P =
0.12). In five initial tumours, more than 25% ofthe cells were Bcl-
2 positive (Figure 1B), and two ofthe controls were positive. Two
of these five cases remained Bcl-2 positive after radiotherapy and
three became negative. In none ofthe cases did Bcl-2 become up-
regulated after treatment.
Tunel
TUNEL was strongly expressed in four of the eight initial carci-
noma biopsies (Figure IC), was expressed in one and negative in
two (one specimen was lost during processing). It was present in
one of the controls (P = 0.08). After treatment, only three cases
showed TUNEL; ofwhich two did not show TUNEL before treat-
ment (cases 5 and 7). Two cases (cases 1 and 6) showed the reverse
situation, i.e. they apparently lost their TUNEL positivity after
given therapy (Table 1). Importantly, all cases with TUNEL posi-
tivity showed conventional morphological criteria of apoptosis.
There was no difference in the expression of TUNEL between
initial tumour specimens and specimens taken after treatment
(P < 0.89). There was no positive correlation between expression
of Bcl-2 and TUNEL (P = 0.5). All tumours were moderately to
well-differentiated squamous cell carcinomas, and TUNEL paral-
leled conventional morphological criteria for apoptosis.
DISCUSSION
Several anti-cancer drugs and radiotherapy act via a cascade of
biochemical events of which several eventually induce apoptosis
(Ijiri and Potten, 1983; Meyn et al, 1993; Ling et al, 1994; Dewey
et al, 1995; Moreira et al, 1995; Stapper et al, 1995). Ligation of
Fas by anti-Fas antibodies or its specific ligand rapidly induces
British Journal ofCancer (1997) 76(2), 175-179 0 CancerResearch Campaign 1997178 HB Helquist etal
apoptosis in vitro and in vivo (Trauth et al, 1989; Itoh et al, 1991;
Ogasawara et al, 1993), and some cytotoxic T cells kill their
targets in a calcium-independent manner via activation of Fas
(Rouvier et al, 1993). Most ofthe signal transduction events distal
to Fas ligation have yet not been fully elucidated but several
reports indicate that Fas-induced apoptosis is mediated via a
ceramide-initiated ras signalling pathway (Gulbins et al, 1995). In
the present study, we did not study transduction signals but inves-
tigated Fas, Bc1-2 and apoptosis in human squamous cell carci-
noma cells in vivo. The results indicate that Fas is present in lung
squamous cell carcinomas but not in the potential precursor cell
(P < 0.001). This has not been reported before. In the specimens
taken after radiotherapy, Fas was apparently lacking (P = 0.03).
We interpret this as a selection oftumour cells rather than a down-
regulation of Fas. Certain Fas-positive tumour cells will die
because ofradiotherapy, and if one of the pathways to death is via
the Fas receptor the absence ofFas after therapy could probably be
explained by these Fas-positive cells having been selected out. If
Fas is present on tumour cells in vivo and not on normal bronchial
epithelial cells, this may have important therapeutic implications.
In a previous study bcl-1 was reported to be amplified in poorly
differentiated squamous cell carcinoma of the lung (Berenson et
al, 1990), but bcl-l [on chromosome 11, t(11;14)(q13;q32)] is
different in several respects in comparison to bcl-2 [on chromo-
some 14, t(14;18)(q32;q21)], and hence comparison is not rele-
vant. A few reports have been published demonstrating a weak to
moderate expression ofBcl-2 protein in squamous cell carcinomas
of, forexample, uterine cervical squamous cell carcinoma (Uehara
et al, 1995) and skin carcinomas (Cerroni et al, 1994; Sleater et al,
1994). In a large study of 126 lung carcinomas, 40 cases were
squamous cell carcinomas and only 25% of these expressed Bcl-2
(Ritter et al, 1995). In none ofthese studies was Bcl-2 shown to be
an independent prognostic factor. Similarly, our present study did
not show any overexpression ofBcl-2 compared with controls and
nor was it shown to be of any prognostic value. Pezzella et al
(1993) detected Bcl-2 in 25% of their lung squamous cell carci-
nomas and, to our knowledge, this is the only study in which a
significant correlation has been found between the expression of
Bcl-2 and prognosis. Tormanen et al (1995) reported 28% oftheir
lung squamous cell carcinomas to be Bcl-2 positive but did not
find Bcl-2 to be an independent prognostic factor. We similarly
found that apoptosis (TUNEL) is not correlated with the expres-
sion ofBcl-2 (P = 0.5). The TUNEL positivity in our present study
correlated well in all cases with apoptotic morphology. Several
tumours had more than 25% TUNEL-positive cells (Table 1). This
is a high apoptotic rate indeed but can probably be explained in
part by the nature of the biopsy specimens. Bronchial specimens
are naturally very small and may represent superficial, partly dead
and almost exfoliated parts of the tumours, and they therefore
show a high apoptotic rate. There are studies that indicate that
overexpression of Bcl-2 protein favours a prolonged survival of
normal as well as ofneoplastic cells (Vaux et al, 1988; Nunez et al,
1990; Doglioni et al, 1994; Pilotti et al, 1994). Yet other studies
have demonstrated that overexpression of Bcl-2 results in resis-
tance to chemotherapy, suggesting that Bcl-2 interferes and
prevents chemotherapy-induced apoptosis (Dole et al, 1994;
Hashimoto et al, 1995). The present findings, i.e. the relatively low
levels of Bcl-2 and the finding that Bcl-2 is not an independent
prognostic factor, are thus in agreement with most previous obser-
vations. All tumours but one in the present series were treated with
radiotherapy, and chemotherapy has not yet been planned or
performed. Radiotherapy did apparently not affect the expression
ofBcl-2 (Table 1).
The important paper by Tormanen et al (1995) shows that
enhanced apoptosis predicts shortened survival in non-small-cell
lung carcinoma. This finding could not be confirmed in the present
series, which may have numerous explanations. They correlated
apoptosis with rate of cell proliferation, immunoreactivity of p53
and Bcl-2, morphological tumour necrosis and survival data
(Tormanen et al, 1995). Our principal aim was to investigate Fas
and, to a lesser extent, Bcl-2 and apoptosis (by TUNEL and
histology) rather than a careful statistical analysis between exam-
ined parameters and survival rate. Although a pilot study, our
results indicate a novel finding that human squamous (non-small)
cell carcinomas express Fas in vivo and also that the receptor is no
longer detectable after radiotherapy. These observations need to be
confirmed in a larger series of tumours, and also in vitro, as they
may have both prognostic and theurapeutic implications.
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